Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Synthetic modified vaccinia Ankara vaccines confer potent monkeypox immunity in non-human primates and healthy adults

Flavia Chiuppesi, John A. Zaia, Sandra Ortega Francisco, Minh Ly, Felix Wussow, View ORCID ProfileDon J. Diamond
doi: https://doi.org/10.1101/2022.07.26.22277958
Flavia Chiuppesi
1Department of Hematology and HCT and Hematologic Malignancies Research Institute, Center for Gene Therapy, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, 91010
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: fchiuppesi@coh.org ddiamond@coh.org
John A. Zaia
1Department of Hematology and HCT and Hematologic Malignancies Research Institute, Center for Gene Therapy, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, 91010
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sandra Ortega Francisco
1Department of Hematology and HCT and Hematologic Malignancies Research Institute, Center for Gene Therapy, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, 91010
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Minh Ly
1Department of Hematology and HCT and Hematologic Malignancies Research Institute, Center for Gene Therapy, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, 91010
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Felix Wussow
1Department of Hematology and HCT and Hematologic Malignancies Research Institute, Center for Gene Therapy, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, 91010
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Don J. Diamond
1Department of Hematology and HCT and Hematologic Malignancies Research Institute, Center for Gene Therapy, City of Hope National Medical Center, 1500 E. Duarte Road, Duarte, CA, 91010
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Don J. Diamond
  • For correspondence: fchiuppesi@coh.org ddiamond@coh.org
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Summary

The recent outbreak of monkeypox (MPXV) outside its endemic boundaries has attracted global attention and prompted world leaders to reserve millions of doses of the only approved third-generation smallpox/MPXV vaccine, Jynneos, which is based on the highly attenuated modified vaccinia Ankara (MVA) vector. We previously developed COH04S1, a multiantigen SARS-CoV-2 vaccine built on a synthetic MVA (sMVA) platform. COH04S1 was extensively tested for efficacy and immunogenicity in animal models, including non-human primates (NHP), and was found to be safe and to induce SARS-CoV-2-specific immunity in a Phase 1 clinical trial in healthy adults. Here we demonstrate that one or two vaccinations of NHP with either COH04S1 or sMVA elicit robust othopoxvirus-specific binding and neutralizing antibody responses. Furthermore, healthy adults vaccinated with COH04S1 at different dose levels develop robust othopoxvirus-specific humoral and cellular immune responses that are durable for over six months post-vaccination. Importantly, both COH04S1 and sMVA vaccinations induce elevated and sustained antibody responses to MPXV-proteins that are major targets of protective neutralizing antibodies. These results demonstrate that COH04S1 and sMVA are valuable vaccine candidates to stimulate robust orthopox/MPXV-specific humoral and cellular immunity.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

NCT04639466

Funding Statement

The Carol Moss Foundation provided funding for this study.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

IRB of the City of Hope National Medical Center gave full ethical approval of this work under COHIRB#20447.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • In this revised version of the manuscript, results showing induction of orthopoxviral-specific binding and neutralizing antibodies in sMVA- and COH04S1-vaccinated non-human primates (NHP) were included. These results prove that both sMVA and sMVA-based COVID-19 vaccine COH04S1 induced orthopoxviral-specific immunity. Additionally, new results showing induction in NHP and healthy adults of monkeypox (MPXV)-specific antibodies binding to MPXV proteins that are a target of protective neutralizing antibodies were added. These new results show that sMVA-based vaccines promote induction of cross-reactive antibodies targeting MPXV proteins with potential protective outcome. The title, results section and discussion were modified to reflect these new findings.

Data Availability

All data produced in the present work are contained in the manuscript

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted August 11, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Synthetic modified vaccinia Ankara vaccines confer potent monkeypox immunity in non-human primates and healthy adults
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Synthetic modified vaccinia Ankara vaccines confer potent monkeypox immunity in non-human primates and healthy adults
Flavia Chiuppesi, John A. Zaia, Sandra Ortega Francisco, Minh Ly, Felix Wussow, Don J. Diamond
medRxiv 2022.07.26.22277958; doi: https://doi.org/10.1101/2022.07.26.22277958
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Synthetic modified vaccinia Ankara vaccines confer potent monkeypox immunity in non-human primates and healthy adults
Flavia Chiuppesi, John A. Zaia, Sandra Ortega Francisco, Minh Ly, Felix Wussow, Don J. Diamond
medRxiv 2022.07.26.22277958; doi: https://doi.org/10.1101/2022.07.26.22277958

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (228)
  • Allergy and Immunology (504)
  • Anesthesia (110)
  • Cardiovascular Medicine (1238)
  • Dentistry and Oral Medicine (206)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (531)
  • Epidemiology (10021)
  • Forensic Medicine (5)
  • Gastroenterology (499)
  • Genetic and Genomic Medicine (2453)
  • Geriatric Medicine (238)
  • Health Economics (479)
  • Health Informatics (1643)
  • Health Policy (752)
  • Health Systems and Quality Improvement (636)
  • Hematology (248)
  • HIV/AIDS (533)
  • Infectious Diseases (except HIV/AIDS) (11864)
  • Intensive Care and Critical Care Medicine (626)
  • Medical Education (252)
  • Medical Ethics (75)
  • Nephrology (268)
  • Neurology (2280)
  • Nursing (139)
  • Nutrition (352)
  • Obstetrics and Gynecology (454)
  • Occupational and Environmental Health (536)
  • Oncology (1245)
  • Ophthalmology (377)
  • Orthopedics (134)
  • Otolaryngology (226)
  • Pain Medicine (157)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (730)
  • Pharmacology and Therapeutics (313)
  • Primary Care Research (282)
  • Psychiatry and Clinical Psychology (2280)
  • Public and Global Health (4833)
  • Radiology and Imaging (837)
  • Rehabilitation Medicine and Physical Therapy (491)
  • Respiratory Medicine (651)
  • Rheumatology (285)
  • Sexual and Reproductive Health (238)
  • Sports Medicine (227)
  • Surgery (267)
  • Toxicology (44)
  • Transplantation (125)
  • Urology (99)